BioMérieux
Provides diagnostic solutions which determine the source of disease and contamination to improve patient health and ensure consumer safety.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor investor investor investor investor investor investor investor | €0.0 | round |
* | N/A | N/A | IPO |
| Total Funding | 000k | ||
| EUR | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | 17 % | 8 % | 6 % | 2 % | 8 % | 7 % | 8 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | 26 % | 31 % | 26 % | 23 % | 24 % | - | - |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | 13 % | 18 % | 13 % | 10 % | 11 % | - | - |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 13 % | 12 % | 12 % | 13 % | 12 % | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
bioMérieux is a global leader in the field of in vitro diagnostics, specializing in innovative solutions to combat infectious diseases and antimicrobial resistance. The company serves healthcare providers, laboratories, and public health organizations worldwide. Operating in the medical diagnostics market, bioMérieux's business model revolves around the development, manufacturing, and distribution of diagnostic tests and systems. These products help detect and manage infectious diseases, ensuring timely and accurate diagnosis, which is crucial for effective treatment. Revenue is generated through the sale of diagnostic instruments, reagents, and software solutions, as well as through service contracts and partnerships. The company is committed to public health and leverages its expertise to address global health challenges, including the growing threat of antimicrobial resistance.
Keywords: in vitro diagnostics, infectious diseases, antimicrobial resistance, healthcare, laboratories, diagnostic tests, medical diagnostics, public health, diagnostic instruments, reagents.
Tech stack
